XML 79 R54.htm IDEA: XBRL DOCUMENT
v3.20.4

Acquisitions and Divestiture (Asset Acquisitions) (Details) - USD ($) $ in Millions | 1 Months Ended | 12 Months Ended
--- | --- | ---
Nov. 30, 2020 | Oct. 31, 2020 | Jun. 30, 2020 | May 31, 2020 | Mar. 31, 2020 | Sep. 30, 2019 | Jul. 31, 2019 | Apr. 30, 2019 | Mar. 31, 2019 | Jan. 31, 2019 | Dec. 31, 2018 | Nov. 30, 2018 | Oct. 31, 2018 | Jul. 31, 2018 | Jun. 30, 2018 | Apr. 30, 2018 | Dec. 31, 2020 | Dec. 31, 2019 | Dec. 31, 2018
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 660.4 | $ 239.6 | $ 1,980.0
Sitryx Therapeutics Limited |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  |  |  | $ 52.3 |  |  |  |  |  |  |  |  |  |  |  |  |  |
AbCellera Biologics Inc. (AbCellera) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  |  | $ 25.0 | $ 25.0 |  |  |  |  |  |  |  |  |  |  |  | 25.0 |  |
Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  |  | 20.0 |  |  |  |  |  |  |  |  |  |  |  |  | 20.0 |  |
Undisclosed |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  |  | $ 174.8 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Evox Therapeutics Ltd |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  | $ 22.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Innovent Biologics, Inc. (Innovent) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  | $ 200.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 200.0 |  |
Disarm Therapeutics, Inc. (Disarm) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  | $ 126.3 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Fochon Pharmaceuticals, Ltd. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges | $ 40.0 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
AC Immune SA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  |  |  |  | $ 30.2 |  |  |  | $ 96.9 |  |  |  |  |  |  |  | $ 127.1 |
ImmuNext, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  |  |  |  |  |  |  | $ 40.0 |  |  |  |  |  |  |  |  |  |
Avidity Biosciences, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  |  |  |  |  |  | $ 25.0 |  |  |  |  |  |  |  |  |  |  |
Centrexion Therapeutics Corporation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  |  |  |  |  | $ 47.5 |  |  |  |  |  |  |  |  |  |  |  |
Sigilon Therapeutics, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 66.9 |  |  |
AurKa Pharma Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 81.8 |  |  |  |
ARMO BioSciences, Inc. (ARMO) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,475.8 |  |  |  |
Anima Biotech Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 30.0 |  |  |  |  |
SIGA Technologies, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  |  |  |  |  |  |  |  |  |  |  | $ 80.0 |  |  |  |  |  |
Chugai Pharmaceutical Co., Ltd. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  |  |  |  |  |  |  |  |  |  |  | $ 50.0 |  |  |  |  |  |
NextCure, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  |  |  |  |  |  |  |  |  |  | $ 28.1 |  |  |  |  |  |  |
Dicerna Pharmaceuticals Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  |  |  |  |  |  |  |  |  | $ 148.7 |  |  |  |  |  |  |  |
Hydra Biosciences |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquired IPR&D charges |  |  |  |  |  |  |  |  |  |  | $ 22.6 |  |  |  |  |  |  |  |

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_SitryxTherapeuticsLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_AbCelleraBiologicsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_JunshiBiosciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_UndisclosedAssetAcquisitionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_EvoxTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_InnoventBiologicsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_DisarmTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_FochonPharmaceuticalsLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_ACImmuneSAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_ImmuNextInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_AvidityBiosciencesInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_CentrexionTherapeuticsCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_SigilonTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_AurkaPharmaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_ARMOBiosciencesInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_AnimaBiotechMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_SIGATechnologiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_ChugaiPharmaceuticalCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_NextCureInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_DicernaPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lly_HydraBiosciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |